Long-term survival in patients with CNSm remains a topic of debate; their bad prognosis could be changing towards improvement. Clinical findings are typically overlooked in CNSm reports and prognostic scales. After our findings, we propose to include them in forthcoming studies to aid prognostic considerations. Factors associated with prolonged survival found in our study include female gender, timing of CNSm diagnosis, occipital lobe location, and single CNSm.
In cancer patients with CVD, thrombocytopenia at the time of CVD diagnosis and altered mental status during initial clinical evaluation were associated with higher mortality, which should be confirmed in future studies.
Background: Thyroid cancer (TC) is the most common endocrine cancer. The majority of patients reach long survival rates, but 10-15% of patients show recurrent disease, and 5% have distant metastases. Brain metastases (BMs) from TC are rare and carry high morbidity and mortality.Methods: From January 2010 to December 2015, nearly 400 patients with TC were treated at a tertiary referral center. This study reports the findings of all seven patients with BM, which were compared to historical controls.Results: Male patients and older age are associated with a higher frequency of distant metastases from TC. Among patients with BM, surgical excision when indicated, followed by whole brain radiotherapy, was the treatment associated with longest survival rates.
Conclusion:Thyroglobulin was the most useful serum marker to diagnose recurrence or distant disease. High levels of thyroglobulin (mean: 15,029; IQR: 300 -13,687) were mainly associated with BMs.
Introduction: In order to optimize clinical and therapeutic approaches for patients with brain metastasis (BM), prognostic markers need to be widely available and simple to execute. Objective: Considering that a Complete-Blood-Count is usually obtained at the initial routine work-up of almost all oncologic patients, the aim of this study was to determine the utility of the neutrophil-to-lymphocyte-ratio (NLR) and the platelet-to-lymphocyte-ratio (PLR) as prognostic markers for BM. Results: A total of 550 patients with systemic cancer were included. Median age at the time of cancer diagnosis was 49 years and median age at the time of BM was 51 years. Median followup time was 11.2 months. Employing NLR cutoff values at BM diagnosis, patients were divided into groups I to III (I: <3, II: 3-4.49, III: >4.5), and median overall survival (MOS) was calculated for each one (I: 20 months, II: 13.9 months, and III: 7.5 months). Groups divided by a PLR cutoff (I: 250, II: ≥250) also differed in MOS (13.9 vs. 9.3 months). After multivariable analysis, only NLR was a significant independent predictor of MOS [I vs. II: 1.5 Odds Ratio (OR); I vs. III: 1.9 OR], meaning that NLR obtained at the time of BM diagnosis was inversely associated with MOS. Conclusion: The NLR, but not the PLR, is predictive of outcome in cancer patients with BM, therefore, NLR might serve as a complement to the already known prognostic scales.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.